Xing F, Persaud Y, Pratilas C, Taylor B, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit D. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene, 31(4):446-57, 2012. Jul 4 2011 [Epub ahead of print]. PMID: 21725359. PMCID: PMC3267014.
Poulikakos P, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Bjoern Titz B, Gabay MT, Salton M, Dahlman K, Tadi M, Wargo J, Flaherty K, Kelley M, Misteli T, Chapman P, Sosman J, Graeber T, Ribas A, Lo R, Rosen N, Solit D. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377):387-90, 2011 Nov 23 [Epub ahead of print]. PMID: 22113612. PMCID: PMC3266695.
Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D’Angelica M, Viale A, Heguy A, Paty P, Chan T, Saltz L, Weiser M, Solit D. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol, 2012 20;30(24):2956-62. Jun 4. [Epub ahead of print]. PMID: 22665543. PMCID: PMC3417049.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen C, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D*, Bardelli A*. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012 Jun 28; 486(7404):532-6. PMID: 22722830. (*The last two authors contributed equally to this study).
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J, Davis A, Mongare M, Gould J, Frederick D, Cooper Z, Chapman P, Solit D, Lo R, Flaherty K, Ogino S, Wargo J, Golub T. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012 Jul 26;487(7408):500-4, Jul 4. [Epub ahead of print]. PMID: 22763439. PMCID: PMC3711467.
Iyer G, Hanrahan A, Milowsky M, Al-Ahmadie H, Scott S, Janakiraman M, Pirun M, Sander C, Socci N, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan T, Bochner B, Bajorin D, Berger M, Taylor B, Solit D. Genome sequencing identifies a basis for everolimus sensitivity. Science, 2012 338(6104):221. Aug 23. [Epub ahead of print]. PMID: 22923433.
Iyer G, Al-Ahmadie H, Schultz N, Hanrahan A, Balar A, Kim P, Lin O, Weinhold N, Sander C, Ostrovnaya I, Zabor E, Janakiraman M, Garcia-Grossman I, Heguy A, Viale A, Bochner B, Reuter V, Bajorin D, Milowsky M, Taylor B, Solit D. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol, 2013 Jul 29. PMID: 23897969.
Cancer Genome Atlas Network, Comprehensive molecular characterization of urothelial bladder cancer. Nature, 2014 Jan 29 [Epub ahead of print]. PMID: 24476821.
Nissan M, Pratilas C, Jones A, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan A, Yao Z, Merghoub T, Ribas A, Chapman P, Yaeger R, Taylor B, Schultz N, Berger M, Rosen N, Solit DB. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res, 2014 Feb 27. [Epub ahead of print]. PMID: 24576830.